Muecksch, Frauke

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,853

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 1,674

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,343

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,308

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 795

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H. H., Barnes, C. O., Cipolla, M., Ramos, V., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 721

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Hacisuleyman, E., Hale, C., Saito, Y., Blachere, N. E., Bergh, M., Conlon, E. G., Schaefer-Babajew, D. J., DaSilva, J., Muecksch, F., Gaebler, C., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 716

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine

SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing

Cited by 572

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffmann, H.-H., Oliveira, T. Y., Oren, D. A., et al. (2021) · Science Translational Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 475

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 433

Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients

Muecksch, F., Wise, H., Batchelor, B., Squires, M., Semple, E., Richardson, C., McGuire, J., Clearly, S., Furrie, E., Greig, N., et al. (2021) · The Journal of Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing

Cited by 308

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Schäfer, A., Muecksch, F., Lorenzi, J. C. C., Leist, S. R., Cipolla, M., Bournazos, S., Schmidt, F., Maison, R. M., Gazumyan, A., Martinez, D. R., et al. (2021) · Journal of Experimental Medicine

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 305

Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost

Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Ben Tanfous, T., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B., et al. (2022) · Nature

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 297

Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination

Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 275

HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization

Bou-Nader, C., Muecksch, F., Brown, J. B., Gordon, J. M., York, A., Peng, C., Ghirlando, R., Summers, M. F., Bieniasz, P. D., & Zhang, J. (2021) · Cell Host & Microbe

HIV Research and TreatmentHIV/AIDS drug development and treatment

Cited by 48

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Lorenzi, J. C. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 39

Transcription of HIV-1 at sites of intact latent provirus integration

Teixeira, A. R., Bittar, C., Silva Santos, G. S., Oliveira, T. Y., Huang, A. S., Linden, N., Ferreira, I. A. T. M., Murdza, T., Muecksch, F., Jones, R. B., et al. (2024) · The Journal of Experimental Medicine

HIV Research and TreatmentVirus-based gene therapy research

Cited by 21